Crossmark

Mortality and clinical outcomes of colistin versus colistin-based combination therapy for infections caused by Multidrug-resistant Acinetobacter baumannii in critically ill patients

Crossref DOI link: https://doi.org/10.1186/s12879-025-10781-1

Published Online: 2025-03-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Alwazzeh, Marwan J. https://orcid.org/0000-0002-4646-6717
Algazaq, Jumanah https://orcid.org/0000-0003-4774-8975
Al-Salem, Fatimah Ali https://orcid.org/0009-0005-9779-8024
Alabkari, Fatimah

Alwarthan, Sara M. https://orcid.org/0000-0001-5061-8560
Alhajri, Mashael https://orcid.org/0000-0002-9325-0281
AlShehail, Bashayer M. https://orcid.org/0000-0003-2372-9462
Alnimr, Amani https://orcid.org/0000-0001-5105-6002
Alrefaai, Ahmad Wajeeh https://orcid.org/0009-0001-5370-9094
Alsaihati, Faten Hussain https://orcid.org/0009-0003-8343-8226
Almuhanna, Fahd Abdulaziz https://orcid.org/0000-0003-2169-8391
License Information

Text and Data Mining valid from 2025-03-26

Version of Record valid from 2025-03-26
More Information

Article History

Received: 25 November 2024

Accepted: 11 March 2025

First Online: 26 March 2025

Declarations

:

: The study was conducted according to the Declaration of Helsinki of the World Medical Association on ethical principles of medical research. The research project has been approved by the Institutional Review Board (IRB) at Imam Abdulrahman bin Faisal University (IRB-2024–01–263). The IRB waived the need for informed consent from the patients involved as the data were analyzed retrospectively and anonymously.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below